To The Moon

Full story: https://grafa.com/en/news/united-states/belite-bio-q3-2026-net-loss-30-3-million

Key points

• Belite Bio (NASDAQ:BLTE) reported a third-quarter 2026 net loss of $30.3 million, compared with $21.7 million a year earlier, as research and administrative expenses increased.

• The company held $271.3 million in cash and cash equivalents and $502.7 million in U.S. Treasury investments at September 30.

• Its tinlarebant application for Stargardt disease has received FDA priority review, with a February 12, 2027 target decision date, while applications have also been submitted in four other countries.

Belite Bio (NASDAQ:BLTE) reported a third-quarter 2026 net loss of $30.3 million, compared with a $21.7 million loss in the same period of 2025.

The wider loss followed an increase in research and development expenses to $15.5 million from $10.3 million and selling, general and administrative expenses to $21.4 million from $12.7 million.

At September 30, the company held $271.3 million in cash and cash equivalents and $502.7 million in U.S. Treasury bills and notes, compared with $352.9 million and $419.7 million, respectively, at December 31, 2025.

Following the announcement, a verifie

The completed Phase 3 DRAGON trial met its primary endpoint, showing a 35.7% reduction in retinal lesion growth versus placebo, while DRAGON II completed enrollment with 73 participants and PHOENIX enrolled 530 participants ahead of a planned interim analysis.

The FDA granted tinlarebant priority review in August with a February 12, 2027 target action date and confirmed that no advisory committee meeting would be held, while Belite has also submitted regulatory applications in Japan, Singapore, the United Kingdom and Switzerland.